<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04166812</url>
  </required_header>
  <id_info>
    <org_study_id>CAPTO-COPD</org_study_id>
    <nct_id>NCT04166812</nct_id>
  </id_info>
  <brief_title>Change in Airway Peripheral Tone in COPD</brief_title>
  <acronym>CAPTO-COPD</acronym>
  <official_title>Role of Small Airway Dysfunction for Disease Progression in Early COPD - an Observational Two-year Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PD Dr. Henrik Watz, Pulmonary Research Center, LungenClinic Großhansdorf (Principal Investigator)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiesi GmbH, Hamburg, Germany (Funding)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Small airways disease is a pathological feature in mild to moderate COPD, which might be
      causally involved in disease progression. However, there are only limited studies available
      that prospectively identified patients at risk for small airway disease. Our intention is to
      investigate the early phase of the disease. In addition, we thereby want to build up a
      well-defined study population of patients in an early phase of the disease with a rapid
      decrease in lung function as measured by oscillometry and multiple breath washout
      (MBW)-testing. In addition, it is our goal to identify patients in an early stage of disease
      and patients at risk of fast progression and/or rapid decline in lung function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>oscillometry (change in R5-20)</measure>
    <time_frame>24 months</time_frame>
    <description>change in frequency dependence of resistance (R5-20)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>multiple breath washout testing (change in LCI)</measure>
    <time_frame>24 months</time_frame>
    <description>change in global ventilation heterogeneity (lung clearance index, LCI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>multiple breath washout testing (change in Scond)</measure>
    <time_frame>24 months</time_frame>
    <description>change in conductive ventilation heterogeneity (Scond)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>multiple breath washout testing (change in Sacin)</measure>
    <time_frame>24 months</time_frame>
    <description>change in acinar ventilation heterogeneity (Sacin)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>spirometry (change in FEV1)</measure>
    <time_frame>24 months</time_frame>
    <description>change in parameters of central obstruction (forced expiratory volume in one second, FEV1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body plethysmography (change in RV/TLC)</measure>
    <time_frame>24 months</time_frame>
    <description>change in parameters of hyperinflation (residual volume / total lung capacity RV/TLC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body plethysmography (change in sRaw)</measure>
    <time_frame>24 months</time_frame>
    <description>change in specific airway resistance (sRaw)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>health Status (change in SGRQ-c)</measure>
    <time_frame>24 months</time_frame>
    <description>change in quality of life (SGRQ-c)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>health Status (change in CAT)</measure>
    <time_frame>24 months</time_frame>
    <description>change in symptom score (CAT)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>COPD</condition>
  <condition>COPD, Early-Onset</condition>
  <arm_group>
    <arm_group_label>patients with early COPD</arm_group_label>
    <description>diagnosis according to current GOLD recommendations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients at risk for COPD</arm_group_label>
    <description>no current diagnosis according to GOLD recommendations, but at risk for COPD</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>oscillometry</intervention_name>
    <description>assessment of peripheral airway resistance using oscillometry</description>
    <arm_group_label>patients at risk for COPD</arm_group_label>
    <arm_group_label>patients with early COPD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>multiple breath washout testing</intervention_name>
    <description>assessment of ventilation heterogeneity using multiple breath washout testing</description>
    <arm_group_label>patients at risk for COPD</arm_group_label>
    <arm_group_label>patients with early COPD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>spirometry</intervention_name>
    <description>assessment of lung function using spirometry</description>
    <arm_group_label>patients at risk for COPD</arm_group_label>
    <arm_group_label>patients with early COPD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>body plethysmography</intervention_name>
    <description>assessment of lung function using body plethysmography</description>
    <arm_group_label>patients at risk for COPD</arm_group_label>
    <arm_group_label>patients with early COPD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>fractional exhaled nitric oxide</intervention_name>
    <description>assessment of eosinophilic airway inflammation using fractional exhaled nitric oxide</description>
    <arm_group_label>patients at risk for COPD</arm_group_label>
    <arm_group_label>patients with early COPD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>transfer factor</intervention_name>
    <description>assessment of gas transfer using single breath transfer factor for carbon monoxide</description>
    <arm_group_label>patients at risk for COPD</arm_group_label>
    <arm_group_label>patients with early COPD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>health status</intervention_name>
    <description>assessment of health status using validated questionnaires (St. George's Respiratory Questionnaire [SGRQ], COPD Assessment Test [CAT])</description>
    <arm_group_label>patients at risk for COPD</arm_group_label>
    <arm_group_label>patients with early COPD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>computed tomography</intervention_name>
    <description>assessment of lung structure and function using computed tomography (only in patients with clinical indication, Heidelberg site)</description>
    <arm_group_label>patients at risk for COPD</arm_group_label>
    <arm_group_label>patients with early COPD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>induced sputum</intervention_name>
    <description>various biomarkers (subgroup of approximately 75 patients, Großhansdorf site)</description>
    <arm_group_label>patients at risk for COPD</arm_group_label>
    <arm_group_label>patients with early COPD</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      venous blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        -  patients at risk for COPD with no current diagnosis according to GOLD recommendations

          -  patients with early COPD with diagnosis according to current GOLD recommendations
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        patients at risk for COPD

        inclusion criteria:

          -  smoking history (at least 10 pack years)

          -  absence of airway obstruction (FEV1/FVC ≥ 70% after salbutamol 400µg)

          -  high symptom score (CAT ≥ 10) or long acting bronchodilator therapy

          -  age &gt; 35 years

        exclusion criteria:

          -  respiratory infection within 4 weeks prior to inclusion

          -  other symptomatic pulmonary disease, except bronchial asthma

        patients with early COPD

        inclusion criteria:

          -  smoking history (at least 10 pack years)

          -  mild COPD (FEV1/FVC &lt; 70% and FEV1 ≥ 70% after salbutamol 400µg)

          -  age &gt; 35 years

        exclusion criteria:

          -  respiratory infection within 4 weeks prior to inclusion

          -  other pulmonary disease, except bronchial asthma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Watz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pulmonary Research Institute at LungClinic Großhansdorf</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederik Trinkmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thoraxklinik at Heidelberg University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henrik Watz, MD</last_name>
    <phone>+49 4102 8881</phone>
    <phone_ext>0</phone_ext>
    <email>H.Watz@pulmoresearch.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frederik Trinkmann, MD</last_name>
    <phone>+49 6221 396</phone>
    <phone_ext>1201</phone_ext>
    <email>frederik.trinkmann@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pulmonary Research Institute at LungClinic Großhansdorf</name>
      <address>
        <city>Großhansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Watz, MD</last_name>
      <phone>+49 4102 8881</phone>
      <phone_ext>0</phone_ext>
      <email>H.Watz@pulmoresearch.de</email>
    </contact>
    <contact_backup>
      <last_name>Anne-Marie Kirsten, MD</last_name>
      <phone>+49 4102 8881</phone>
      <phone_ext>0</phone_ext>
      <email>A.Kirsten@pulmoresearch.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik at Heidelberg University</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederik Trinkmann, MD</last_name>
      <phone>+49 6221 396</phone>
      <phone_ext>1201</phone_ext>
      <email>frederik.trinkmann@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Felix Herth, MD</last_name>
      <phone>+49 6221 396</phone>
      <phone_ext>1201</phone_ext>
      <email>felix.herth@med.uni-heidelberg.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Dr. Frederik Trinkmann</investigator_full_name>
    <investigator_title>Principial Investigator</investigator_title>
  </responsible_party>
  <keyword>small airway disease</keyword>
  <keyword>peripheral airway tone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>data protection rules do not allow to share individual participant data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

